BOC RNA’s siRNA Drug Delivery Platform: Designed to Promote the Rapid Development of RNAi Therapeutic Applications

October 27 18:09 2020
BOC RNA, a sub brand of BOC Sciences, recently announced that it hopes to use its unique siRNA conjugation technology to accelerate the development of effective targeted therapies for cancer and genetic diseases.

New York, USA – October 27, 2020 – Recently, BOC RNA, a sub brand of BOC Sciences, announced that it hopes to use its unique siRNA conjugation technology to accelerate the development of effective targeted therapies for cancer and genetic diseases. BOC RNA has extensive experience in the field of RNAi therapy discovery and development.

The great potential of small interfering RNA (siRNA) in the development of new drugs has been proven. Currently, the FDA has approved the marketing of two siRNA drugs: Patisiran and Givsiran. Patisiran (ONPATTRO®) is used for the treatment of peripheral neuropathy caused by hereditary thyroxine-mediated amyloidosis (hATTR), while Givsiran (GIVLAARI™) is used for the treatment of acute hepatic porphyria (AHP). Many other siRNAs are being evaluated in early to late-stage clinical trials. Since siRNA composed of natural RNA nucleotides is rapidly degraded, it is not easy to reach its target organs during systemic administration. Therefore, it is necessary to improve the stability of siRNA for therapeutic applications.

Direct conjugation of small drug molecules, aptamers, lipids, peptides, proteins, or polymers with siRNA can improve the pharmacokinetic behavior of siRNA in vivo. Regardless of whether such siRNA bioconjugates form nanocomplexes with cationic carriers, they can significantly extend the biological half-life, increase the delivery efficiency to target tissues, and maintaining sufficient gene silencing activity.

BOC RNA can provide the pharmaceutical industry with comprehensive and effective siRNA coupling services to generate the following conjugates to ensure the effective delivery of siRNA drugs:

• GalNAc-siRNA Conjugates
• Antibody-siRNA Conjugates
• Peptide-siRNA Conjugates
• Polymer-siRNA Conjugates
• Cholesterol-siRNA Conjugates
• Nanoparticle-siRNA Conjugates

About BOC RNA

BOC RNA is a leading private biotechnology company dedicated to the discovery and development of RNAi therapeutics. The company’s mission is to develop effective delivery systems to improve the stability and targeting of siRNA, promote the development of RNAi therapeutics, and alleviate human suffering. The members of BOC RNA’s senior scientist team have rich comprehensive experience in siRNA target screening, siRNA synthesis, modification, and in vivo delivery.

For more information, please visit https://rna.bocsci.com.

Media Contact
Company Name: BOC Sciences
Contact Person: Alex Brown
Email: Send Email
Phone: 1-631-619-7922
Country: United States
Website: https://www.bocsci.com

view more articles

About Article Author